27,737 options granted to Bionano Genomics (BNGO) chief operating officer

Rhea-AI Filing Summary

Bionano Genomics chief operating officer Mark Oldakowski received a grant of 27,737 stock options on February 2, 2026. The options give him the right to buy Bionano Genomics common stock at an exercise price of $1.27 per share and expire on February 1, 2036.

The award vests in monthly installments over 48 months, starting one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, he beneficially owns 27,737 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider OLDAKOWSKI MARK

Role CHIEF OPERATING OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	27,737	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 27,737 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OLDAKOWSKI MARK

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.27	02/02/2026		A		27,737		(1)	02/01/2036	Common Stock	27,737	$0	27,737	D

Explanation of Responses:

1. Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bionano Genomics (BNGO) report for its COO?

Bionano Genomics reported that COO Mark Oldakowski received 27,737 stock options on February 2, 2026. These options are a right to buy common shares at a fixed exercise price over time, subject to a specific vesting schedule.

What are the key terms of Mark Oldakowski’s Bionano Genomics stock options?

Mark Oldakowski’s stock options cover 27,737 shares with a $1.27 exercise price per share and a February 1, 2036 expiration. The options were granted at no cost for the derivative itself, with value realized only if exercised above the exercise price.

How do the Bionano Genomics options granted to the COO vest over time?

The options vest monthly over 48 months, beginning one month after the vesting commencement date. This structure means the award gradually becomes exercisable, reaching full vesting on the four-year anniversary of the vesting commencement date.

How many Bionano Genomics derivative securities does the COO own after this Form 4?

After this reported grant, COO Mark Oldakowski beneficially owns 27,737 derivative securities, all in the form of stock options. These are held directly and represent rights to acquire Bionano Genomics common shares under the option terms.

Is the Bionano Genomics COO’s option grant a purchase of existing shares?

No, the filing shows a grant of stock options, not a purchase of existing shares. The grant provides a future right to buy Bionano Genomics common stock at $1.27 per share if the options are exercised after vesting.

What transaction code is used for the Bionano Genomics COO’s option grant?

The Form 4 lists transaction code “A” for the COO’s stock option grant, indicating an award or acquisition. The filing classifies this as a derivative security transaction and notes the options are held directly after the grant.